therapeutic vaccines for alzheimer’s — are we close enough?
TRANSCRIPT
Therapeutic Vaccines for
Alzheimer’s — Are We Close
Enough?
Read Full Report
Alzheimer's disease (AD) a major
cause of Dementia today across the
world
Read Full Report
By 2030 nearly 63% of
Alzheimer cases will be in low
or middle-income countries
Read Full Report
From 1998-2014 only 4 drugs
have been approved by the FDA
leading to 1:30 ratio of successful
therapy
Read Full Report
The cost of Alzheimer treatment
could reduce by $367 billion
(by 2050)
Read Full Report
Global market for Alzheimer’s
treatment expected to grow at a CAGR
of 10.5% from $4.9 billion in 2013 to
$13.3 billion by 2023
Read Full Report
The United States, accounts for nearly
40% of AD therapeutics market share
and tops in terms of innovator
geography
Read Full Report
Could a vaccine for Alzheimer’s be a reality any sooner?
Find more on Alzheimer Therapy Market Challenges from Aranca’s Technology
Intelligence & IP Research Experts.
Read Full Report Explore our work